A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

by Casero, J.L, Clematis Study Group, d'Ardhuy, X.L, Derks, M., Fontoura, P., Goeldner, C., Hernandez, M.-C, Hipp, J.F, Khwaja, O., Kishnani, P.S, Lennon-Chrimes, S., Noeldeke, J., Pellicer, S., Skotko, B.G, Squassante, L., Visootsak, J., Wandel, C.
Published 2022